NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP

Active Not RecruitingN/A

Sponsor: Midway Specialty Care Center

Conditions: Hiv

Interventions: Cabotegravir Injection [Apretude]

Countries: United States

Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Cisgender females, ages 18 years and older
2. Negative HIV test at baseline
3. Negative Pregnancy test at baseline
4. Weigh at least 35 kilograms
5. Already Prescribed CAB-LA (Apretude)

Exclusion Criteria:

1. Transgender females or males
2. Cisgender males
3. Cisgender female who is actively breastfeeding
4. Severe hepatotoxicity
5. Evidence of Hepatitis B Infection
6. History or presence of allergies to cabotegravir or its components

Locations (3)

Orlando, Florida, United States
Temple Terrace, Florida, United States
West Palm Beach, Florida, United States